[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Xinxiang Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,44,79,103,129,148,169,191,210,237,258,277,292,312,332,361,385,412,432,464,483,509,535,555,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641836","multi-omics-insights-into-androgenetic-alopecia-100641836",false,"NCT07603544","Multi-Omics Insights Into Androgenetic Alopecia","Multi-Omics Analysis of the Hair Follicle Microenvironment in Androgenetic Alopecia for Mechanistic Study and Target Identification","Inclusion Criteria:\n\n* Age and Gender: Males aged 25-30 or 60-65 years.\n* Diagnosis: Patient Group: Diagnosed by a physician with Hamilton-Norwood Stage III androgenetic alopecia (AGA). Healthy Control Group: Healthy scalp with no signs of hair loss.\n* Medication and Treatment History: No use of anti-hair loss medications (e.g., minoxidil, finasteride), hormonal drugs, or scalp chemical treatments (perm or dye) within the last 6 months.\n* Informed Consent: Voluntarily signed and provided written informed consent.\n\nExclusion Criteria:\n\n* Scalp Conditions: Presence of other types of alopecia (besides AGA) or active scalp diseases (e.g., psoriasis, dermatitis, infections).\n* Medical History: History of keloids or coagulation disorders.\n* Systemic Diseases: Major underlying conditions, including severe cardiovascular\u002Fcerebrovascular diseases, immune system disorders, or malignant tumors.\n* Allergies: Known hypersensitivity to local anesthetics.\n* Prior Clinical Trials: Participation in any other clinical trials within 3 months prior to screening.\n* Other Factors: Any other conditions deemed unsuitable for participation by the investigator.",true,"MALE","20 Years","65 Years",{"count":22,"type":23},12,"ESTIMATED","OBSERVATIONAL","This study utilizes a multi-omics approach to systematically characterize the cellular heterogeneity and spatial architecture of the hair follicle microenvironment in patients with androgenetic alopecia (AGA). Our primary aim is to elucidate the key mechanisms driving hair follicle stem cell (HFSC) exhaustion and to identify potential therapeutic targets. Investigators will collect six groups of scalp tissue samples, which include healthy controls and AGA patients (stratified into younger and older cohorts). By integrating spatial transcriptomics, single - cell sequencing data, investigators will map aberrant cell subpopulations and their complex interaction networks. Furthermore, the identified core targets will be functionally validated using patient-derived organoids and animal models. Expected outcomes include the identification of 3-5 critical cell subpopulations and the discovery of 8-10 disease-associated targets. Additionally, investigators will establish an integrated clinical-omics-validation database, providing a robust theoretical foundation for the precision diagnosis and treatment of AGA.",[27],"Androgenetic Alopecia (AGA)",[29,30],"single-cell RNA sequencing","spatial transcriptomics","RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":35},"2026-03-08",{"date":39,"type":23},"2027-03",{"name":41,"class":42},"The First Affiliated Hospital of Xinxiang Medical College","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":20,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100643302","early-phase-1-thermosensitive-gel-nasal-spray-with-stem-cell-exosomes-mupirocin-and-dnase-i-for-chronic-sinusitis-100643302","NCT07635433","Thermosensitive Gel Nasal Spray With Stem Cell Exosomes, Mupirocin, and DNase I for Chronic Sinusitis","A Single-Centre, Randomised, Double-Blind, Placebo-Controlled Exploratory Clinical Study of a Thermosensitive Gel Nasal Spray Loaded With Umbilical Cord Mesenchymal Stem Cell Exosomes, Mupirocin and DNase I for the Treatment of Chronic Rhinosinusitis (Chronic Type Without Polyps)","Inclusion Criteria:\n\n* Age 18 to 65 years, both genders\n* Diagnosis of chronic rhinosinusitis without nasal polyps according to Chinese guidelines (2018), duration \\>12 weeks\n* Nasal endoscopy shows purulent secretions (Lund-Kennedy secretion score ≥1)\n* Nasal secretion culture positive for Staphylococcus aureus\n* Sino-Nasal Outcome Test-22 (SNOT-22) score ≥30\n* Voluntary signed informed consent\n\nExclusion Criteria:\n\n* Sinus surgery within past 6 months, or anatomical abnormalities requiring reoperation\n* Confirmed allergic fungal rhinosinusitis, odontogenic rhinosinusitis, or nasal polyps\n* Nasal discharge culture indicating Pseudomonas aeruginosa as primary pathogen\n* Primary ciliary dyskinesia, cystic fibrosis, or severe immunodeficiency\n* Use of systemic antibiotics or immunosuppressants within past 4 weeks\n* Use of intranasal corticosteroids within past 2 weeks\n* Hypersensitivity to mupirocin, DNase I, or any component of the formulation\n* Severe renal impairment (estimated Glomerular Filtration Rate, eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²)\n* Pregnant, breastfeeding, or planning to become pregnant during the study\n* Uncontrolled severe systemic diseases (diabetes, hypertension, autoimmune diseases)\n* Malignancy within past 5 years\n* Participation in other clinical trials","ALL","18 Years",{"count":54,"type":23},108,"INTERVENTIONAL",[57],"EARLY_PHASE1","This study tests a new nasal spray for adults (18-65 years) with chronic rhinosinusitis (CRS) without nasal polyps. The spray contains a temperature-sensitive gel (thermosensitive gel) that turns into a soft gel inside the nose to slowly release three active ingredients: human umbilical cord mesenchymal stem cell exosomes (hUC-MSC-Exo) to help heal the nasal lining, mupirocin (an antibiotic that kills Staphylococcus aureus bacteria), and DNase I (an enzyme that breaks down thick mucus). The study aims to check the safety of this triple combination and see if it can reduce infection, clear mucus, and improve symptoms. Participants will be randomly assigned to one of three groups: triple spray, a dual spray (without exosomes), or a placebo (gel only). The treatment is used twice daily for 4 weeks, with follow-up visits up to day 90. The study is single-centre, double-blind, and placebo-controlled. Outcome measures include safety (adverse events graded by Common Terminology Criteria for Adverse Events version 5.0, CTCAE v5.0), bacterial clearance rate, changes in nasal endoscopy score (Lund-Kennedy), quality of life (Sino-Nasal Outcome Test-22, SNOT-22), and nasal symptom visual analog scale (VAS).",[60],"Chronic Rhinosinusitis With Nasal Polyps",[62,63,64,65,66,67,68,69],"Chronic Rhinosinusitis","Thermosensitive Gel","Nasal Spray","Exosomes","Mupirocin","DNase I","Staphylococcus aureus","Double-Blind","NOT_YET_RECRUITING","2026-06-07",{"date":73,"type":35},"2026-06-09",{"date":75,"type":23},"2026-07-01",{"date":77,"type":23},"2027-06-30",{"name":41,"class":42},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":20,"enrollmentInfo":87,"targetDuration":4,"studyType":55,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":102,"locationsCount":4},"100643419","early-phase-1-thermosensitive-gel-nasal-spray-with-exosomes-azelastine-and-interferon-for-acute-phase-of-chronic-sinusitis-100643419","NCT07635459","Thermosensitive Gel Nasal Spray With Exosomes, Azelastine, and Interferon for Acute Phase of Chronic Sinusitis","A Single-Centre, Randomised, Double-Blind, Placebo-Controlled Exploratory Clinical Study of a Thermosensitive Gel Nasal Spray Containing Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes, Azelastine and Recombinant Human Interferon α-2b for the Treatment of Chronic Rhinosinusitis (Acute Phase)","CRS","Inclusion Criteria:\n\n* Age 18 to 65 years, both genders\n* Diagnosis of chronic rhinosinusitis according to Chinese guidelines (2018) or EPOS 2020, duration \\>12 weeks\n* Lund-Kennedy endoscopic score ≥4\n* SNOT-22 score ≥30\n* Nasal symptoms stable in past month, or acute flare-ups not requiring systemic antibiotics\u002Fsteroids\n* Voluntary signed informed consent\n\nExclusion Criteria:\n\n* Sinus surgery within past 6 months or anatomical abnormalities requiring reoperation\n* Allergic fungal rhinosinusitis, odontogenic rhinosinusitis, or nasal polyps\n* Primary ciliary dyskinesia, cystic fibrosis, or severe immunodeficiency\n* Use of systemic glucocorticoids, immunosuppressants, or antibiotics within past 4 weeks\n* Use of intranasal glucocorticoids, antihistamines, or leukotriene receptor antagonists within past 2 weeks\n* Hypersensitivity to poloxamer, chitosan, azelastine, or interferon\n* Pregnant, breastfeeding, or planning to become pregnant\n* Uncontrolled severe systemic diseases (diabetes, hypertension, autoimmune diseases)\n* Malignancy within past 5 years\n* Participation in other clinical trials",{"count":54,"type":23},[57],"This study tests a new nasal spray for adults (18-65 years) with chronic sinusitis experiencing an acute phase. The spray contains a temperature-sensitive gel that turns into a soft gel inside the nose to slowly release three active ingredients: stem cell exosomes (to repair nasal lining), azelastine (an antihistamine and anti-inflammatory drug), and interferon alpha-2b (an antiviral agent). The study aims to evaluate safety and see if the spray can reduce symptoms, fight viruses, and improve quality of life. Participants will be randomly assigned to one of three groups: triple spray, dual spray (without exosomes), or placebo (gel only). Treatment is twice daily for 4 weeks, with follow-up visits up to day 90.",[91],"Chronic Rhinosinusitis Without Polyps",[62,93,63,64,65,94,95,96,97,98],"Acute Exacerbation","Interferon alpha-2b","Antiviral","Anti-inflammatory","Randomized Controlled Trial","Azelastine",{"date":73,"type":35},{"date":75,"type":23},{"date":77,"type":23},{"name":41,"class":42},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":55,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100638262","clinical-study-of-minocycline-hydrochloride-injectable-hydrogel-for-the-treatment-of-periodontitis-100638262","NCT07611630","Clinical Study of Minocycline Hydrochloride Injectable Hydrogel for the Treatment of Periodontitis","Construction of a Long-Acting Sustained-Release Minocycline Hydrochloride Delivery System Based on Hyaluronic Acid-Nanoclay Composite Hydrogel and Its Application in the Treatment of Periodontitis","Inclusion Criteria:\n\n* Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.\n* Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).\n* Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.\n\nExclusion Criteria:\n\n* Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c \\> 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.\n* Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.\n* Factors Interfering with Healing: Heavy smokers (average \\> 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.\n* Special Physiological Periods: Pregnant or breastfeeding women.\n* Drug Allergy: Known allergy to minocycline (MH), hyaluronic acid (HA), or similar chemical components.","70 Years",{"count":112,"type":23},80,[114],"NA","This study aims to construct and systematically evaluate a multifunctional synergistic drug delivery system based on a hyaluronic acid-nanoclay composite hydrogel to achieve integrated treatment of periodontitis encompassing \"infection control, inflammation regulation, and bone regeneration promotion.\" Through material design, in vitro functional validation, and in vivo efficacy evaluation, the study will elucidate the intrinsic relationships and synergistic mechanisms among \"material structure, controlled drug release, and biological effects\" within this system, thereby providing a theoretical basis and experimental foundation for the development of smart periodontal regenerative materials with clinical translational potential.",[117],"Periodontitis",[117,119,120],"Hydrogel","Minocycline Hydrochloride","2026-05-20",{"date":123,"type":35},"2026-05-28",{"date":125,"type":23},"2026-05-01",{"date":127,"type":23},"2028-12-31",{"name":41,"class":42},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":110,"enrollmentInfo":136,"targetDuration":4,"studyType":55,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":147,"locationsCount":4},"100637686","clinical-study-of-bmp-2-injectable-hydrogel-for-promoting-alveolar-bone-regeneration-100637686","NCT07611617","Clinical Study of BMP-2 Injectable Hydrogel for Promoting Alveolar Bone Regeneration","Study on Injectable Hydrogel Loaded With BMP-2 for Promoting Alveolar Bone Regeneration Induced by Periodontitis","Inclusion Criteria:\n\n* Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.\n* Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).\n* Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.\n* Compliance and Consent: The subject is able to understand the study procedures, voluntarily sign the informed consent form, and commit to returning for follow-up visits as required (1, 3, 6, 12 months).\n\nExclusion Criteria:\n\n* Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c \\> 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.\n* Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.\n* Factors Interfering with Healing: Heavy smokers (average \\> 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.\n* Special Physiological Periods: Pregnant or breastfeeding women.",{"count":112,"type":23},[114],"This project aims to construct an injectable self-healing hydrogel loaded with BMP-2, with optimized gelation time and mechanical strength to meet the requirements for periodontal pocket filling, for the treatment of periodontitis and acceleration of tissue repair, achieving a \"bactericidal-anti-inflammatory-regenerative\" trinity function. This project will provide a novel intelligent material for promoting alveolar bone regeneration in periodontitis and establish a theoretical paradigm for the precise intervention of oral infectious diseases.",[117,140],"Alveolar Bone Loss* \u002F Therapy",[117,142,143,119],"Alveolar Bone Loss* \u002F therapy","BMP-2",{"date":123,"type":35},{"date":125,"type":23},{"date":127,"type":23},{"name":41,"class":42},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":20,"enrollmentInfo":155,"targetDuration":4,"studyType":55,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":168,"locationsCount":43},"100639271","mesenchymal-stem-cells-in-the-treatment-of-burn-wounds-100639271","NCT07580755","Mesenchymal Stem Cells in the Treatment of Burn Wounds","A Randomized Controlled Study on the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Extensive Burns","Inclusion Criteria:\n\n1. Voluntary participation and signing of the informed consent form;\n2. Burn patients, subjects requiring autologous skin grafting;\n3. Age 18 to 65 years old, gender not restricted;\n4. During this clinical study, single person, single donor skin area (lateral thigh or trunk) treatment;\n5. Skin burn area \\\u003C 30% of total body surface area (TBSA);\n6. The donor skin area is the first time for donation, and the donor skin area is medium-thick skin (thickness approximately 0.4mm);\n7. The area of the excised skin flap ≥ 90 cm2;\n8. Able to cooperate with this study protocol and accept regular postoperative follow-up visits.\n\nExclusion Criteria:\n\n1. Those allergic to sodium alginate (gel component);\n2. Electric shock injuries, chemical burns, radiation injuries or combined with other traumas;\n3. Subjects with severe systemic diseases (judged by the researchers);\n4. Subjects with uncontrolled hypertension or diabetes (judged by the researchers);\n5. Pregnant or lactating women;\n6. Subjects whose condition may affect the study assessment or require the concurrent use of medical treatments that may affect the efficacy assessment;\n7. Subjects with acute or chronic kidney diseases, renal failure or serum creatinine level = 1.5 times the upper limit of normal value;\n8. Subjects with acute or chronic liver diseases, total bilirubin, alanine aminotransferase, aspartate aminotransferase = 2.0 times the upper limit of normal value;\n9. Subjects with a history of malignant tumors;\n10. Subjects who have participated in other clinical studies for less than 3 months;\n11. Subjects with mental disorders and without self-awareness, unable to express clearly;\n12. Subjects using immunosuppressants and those who have been using corticosteroids for a long time (more than 1 month) (excluding local application);\n13. Subjects with infectious diseases (any one of the four items positive in the test);\n14. Subjects with other severe systemic diseases;\n15. Other subjects that the researchers consider not eligible for inclusion.",{"count":156,"type":23},90,[114],"Burn patients were randomly divided into the low-dose stem cell gel group, the high-dose stem cell gel group, and the placebo group (with only the gel), and received the same treatment under the same conditions simultaneously.",[160,161],"Burn Injury","Burn Patients","2026-05-05",{"date":164,"type":35},"2026-05-12",{"date":166,"type":23},"2026-04-27",{"date":127,"type":23},{"name":41,"class":42},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":110,"enrollmentInfo":176,"targetDuration":4,"studyType":55,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":190,"locationsCount":4},"100639168","study-on-silk-fibroin-reinforced-collagen-based-composite-membrane-for-periodontal-bone-tissue-regeneration-100639168","NCT07574853","Study on Silk Fibroin-Reinforced Collagen-Based Composite Membrane for Periodontal Bone Tissue Regeneration","Clinical Study of Silk Fibroin-Reinforced Collagen-Based Composite Membrane for Promoting Alveolar Bone Regeneration","Inclusion Criteria:\n\n* Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.\n* Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).\n* Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.\n* Compliance and Consent: The subject is able to understand the study procedures, voluntarily sign the informed consent form, and commit to returning for follow-up visits as required (1, 3, 6, 12 months).\n\nExclusion Criteria:\n\n* Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c \\> 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.\n* Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.\n* Factors Interfering with Healing: Heavy smokers (average \\> 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.\n* Special Physiological Periods: Pregnant or breastfeeding women. Drug Allergy: Known allergy to minocycline (MH), hyaluronic acid (HA), or similar chemical components.",{"count":112,"type":23},[114],"Based on the mechanism of intramembranous ossification of the alveolar bone, it is necessary to design a biomimetic membrane material based on the principle of GBR (Guided Bone Regeneration) to simulate the biological microenvironment of alveolar bone regeneration, promote the direct differentiation of stem cells into osteoblasts and rapid mineralization, thereby achieving the goal of alveolar bone regeneration. This section, based on bionic principles, proposes to enhance the mechanical properties of the collagen membrane with silk fibroin to achieve synergistic regeneration of periodontal bone\u002Fsoft tissue. This project employs silk fibroin-reinforced collagen membrane technology to overcome the dual bottlenecks of insufficient strength and excessively rapid degradation of existing materials; establishes a \"structure-guided, mechanically supported, factor-controlled release\" trinity regeneration strategy to achieve precise repair of periodontal composite tissues. This study will provide new materials and methods for periodontal regeneration and offer a theoretical reference for the combined regeneration of other hard\u002Fsoft tissues.",[140],[181,182,183,184],"Alveolar bone","Collagen","Silk fibroin","Membrane material","2026-05-03",{"date":187,"type":35},"2026-05-08",{"date":125,"type":23},{"date":127,"type":23},{"name":41,"class":42},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":110,"enrollmentInfo":198,"targetDuration":4,"studyType":55,"phases":200,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":209,"locationsCount":4},"100638716","allogeneic-dental-pulp-stem-cells-for-the-treatment-of-periodontitis-100638716","NCT07574840","Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis","Clinical Study of Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis","Inclusion Criteria:\n\n* Disease Diagnosis: Clinically diagnosed with chronic periodontitis (typically Stage III or IV according to the latest periodontal disease classification).\n* Target Tooth Requirements: At least two non-adjacent periodontal pockets with a Probing Pocket Depth (PPD) ≥5 mm.\n* Clinical Attachment Level (CAL) loss ≥3 mm.\n* Evidence of significant alveolar bone resorption on X-ray or CBCT (bone loss exceeding one-third of the root length).\n* Age and General Condition: Typically aged 18-70 years, in good general health, and able to complete the 12-month follow-up.\n* Oral Hygiene Awareness: Subjects are willing to receive conventional periodontal basic treatment (SRP) and demonstrate a good willingness to maintain oral hygiene (e.g., plaque index controlled at a low level).\n\nExclusion Criteria:\n\n* Systemic Diseases: Presence of severe, uncontrolled systemic diseases (e.g., diabetes with HbA1c \\>7%, active hepatitis, tuberculosis). History of malignancy or immunodeficiency diseases (due to the proliferative potential of stem cells, cancer risk must be strictly excluded).\n* Local Interfering Factors: Target teeth with severe mobility (Grade III mobility) or non-restorable residual crowns\u002Froots. Received periodontal surgical treatment or systemic antibiotics within the past 3 months.\n* Special Populations and Habits: Heavy smokers (typically defined as smoking \\>10 cigarettes per day), as smoking significantly inhibits the regenerative effect of stem cells and local blood supply. Pregnant or breastfeeding women. Individuals allergic to any components of the study preparation (e.g., specific biological carriers).",{"count":199,"type":23},30,[114],"The overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. It aims to develop a stem cell injection therapy that promotes the regeneration of periodontal soft and hard tissues through a non-invasive (minimally invasive) procedure, thereby replacing traditional traumatic periodontal surgery.",[117],[117,204],"Dental pulp stem cells",{"date":187,"type":35},{"date":207,"type":23},"2026-04-15",{"date":127,"type":23},{"name":41,"class":42},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":55,"phases":219,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":4},"100636662","development-and-clinical-study-of-burn-wound-nursing-dressing-based-on-sodium-hyaluronate-carbomer-composite-hydrogel-100636662","NCT07568600","Development and Clinical Study of Burn Wound Nursing Dressing Based on Sodium Hyaluronate Carbomer Composite Hydrogel","Development and Preclinical Study of Nursing Dressing for Ⅰ\u002FShallow Ⅱ Degree Burn Wounds Based on Sodium Hyaluronate Carbomer Composite Hydrogel","Inclusion Criteria:\n\nPartial or full thickness burns requiring split thickness skin grafts Target burn wound size between 10 cm² and 1000 cm² Age ≥ 18 years Ability to read, write, and speak German Provision of voluntary informed consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations Informed consent will be obtained from the patient or from a legal representative if the patient is not able or competent to consent; in such cases, informed consent will also be obtained from the patient when he\u002Fshe regains competence Women of childbearing potential must test negative on a standard urine pregnancy test and must agree to practice appropriate contraceptive methods for the duration of the study (e.g., oral contraceptive, intrauterine device \\[IUD\\], intramuscular contraceptive, abstinence)\n\nExclusion Criteria:\n\nTarget wound has exposed hyaline cartilage Connective tissue disorder Previous skin graft failure at target wound site Total burn surface area ≥ 70% Infected target wound Immunosuppression therapy Chronic hemodialysis Steroid use Diabetes (Type I) Allergy or sensitivity to any of the ingredients in Prontosan® Wound Gel X Allergy or sensitivity to chlorhexidine Pregnancy Simultaneous participation in another clinical trial","55 Years",{"count":199,"type":23},[114],"Development and clinical study of burn wound nursing dressing based on sodium hyaluronate carbomer composite hydrogel",[222,223,224],"Burn","Burn Contracture of Skin","Burn Degree Second",[226,227,228],"hydrogel","epidermal growth factor","Benzalkonium chloride","2026-04-28",{"date":231,"type":35},"2026-05-06",{"date":233,"type":23},"2026-08-15",{"date":235,"type":23},"2028-10-20",{"name":41,"class":42},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":20,"enrollmentInfo":244,"targetDuration":4,"studyType":55,"phases":245,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":43},"100633693","phase-1-humscs-combined-with-col-i-to-third-degree-burn-wound-100633693","NCT07530003","HUMSCs Combined With Col I to Third-Degree Burn Wound","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Exploratory Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Combined With Bovine Type I Collagen for Promoting Third-Degree Burn Wound Repair","Inclusion Criteria:\n\n* Aged 18-65 years, gender unrestricted\n* Confirmed third-degree burns, wound area 1%-5% TBSA\n* Admission within 72 hours after burn injury\n* Voluntarily signed informed consent\n* Able to cooperate and complete follow-up\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Severe immunodeficiency or autoimmune disease\n* History of malignant tumor, or coagulation dysfunction\n* Severe cardiac, hepatic, or renal insufficiency\n* Hypersensitivity to collagen or stem cell components\n* Uncontrollable severe wound infection\n* Participation in other clinical studies within the past 3 months\n* Inability to comply with follow-up",{"count":54,"type":23},[246,247],"PHASE1","PHASE2","To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cells combined with bovine type I collagen in the treatment of third-degree burn wounds.",[250,251],"Burn Wounds","Third-Degree Burn Wounds",{"date":253,"type":35},"2026-05-04",{"date":255,"type":23},"2026-04-06",{"date":127,"type":23},{"name":41,"class":42},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":20,"enrollmentInfo":265,"targetDuration":4,"studyType":55,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":43},"100600177","tissue-engineered-cartilage-to-repairing-articular-cartilage-defects-100600177","NCT07094100","Tissue Engineered Cartilage to Repairing Articular Cartilage Defects","Clinical Study of Cartilage Constructed by Autologous Bone Marrow Mesenchymal Stem Cells in Repairing Articular Cartilage Defects","Inclusion Criteria:\n\n1. The patients' age ranges from 18 to 65 years old, and gender is not restricted;\n2. The imaging results show that the epiphyseal growth is mature;\n3. The defects or localized injuries of joint cartilage caused by trauma or other reasons;\n4. The injured area is the distal weight-bearing surface of the femoral condyle of the knee joint, with no more than 4 lesions, and there is no injury to the cruciate ligaments;\n5. The patients voluntarily sign and provide a written informed consent form and are willing to closely cooperate with the doctor's strict postoperative rehabilitation program.\n\nExclusion Criteria:\n\n1. The patient is extremely overweight, with a body mass index greater than 35;\n2. The lower limb alignment is valgus by more than 10° and varus by more than 5°;\n3. Multiple ligament injuries;\n4. There are numerous bad habits such as heavy smoking, drug abuse, and excessive alcohol consumption;\n5. Has undergone open knee joint surgery within the past six months;\n6. Has severe joint stiffness or fibrosis;\n7. Has an allergic constitution or a history of allergic reactions to collagen;\n8. Has mental abnormalities;\n9. Cannot or is unwilling to undergo rehabilitation training;\n10. Has primary cardiovascular diseases, lung diseases, endocrine and metabolic disorders, or other serious diseases that affect their daily life, such as tumors or AIDS;\n11. Pregnant or lactating women, or those planning to conceive during the trial period;\n12. Other acute or chronic diseases, for which the researchers consider surgery to be inappropriate.",{"count":199,"type":23},[114],"The joint cartilage constructed by combining bone marrow mesenchymal stem cells with three-dimensional materials has achieved the goal of repairing joint cartilage.",[269,270],"Cartilage Injury","OA Knee",{"date":253,"type":35},{"date":273,"type":23},"2026-04-20",{"date":275,"type":23},"2028-12",{"name":41,"class":42},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":20,"enrollmentInfo":283,"targetDuration":4,"studyType":55,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":291,"locationsCount":43},"100600751","clinical-transformation-of-bone-reconstruction-with-autologous-bone-marrow-mesenchymal-stem-cells-in-vitro-to-repair-avascular-necrosis-of-femur-head-100600751","NCT07101562","Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Avascular Necrosis of Femur Head","Inclusion Criteria:\n\n1. Capable of understanding and voluntarily signing the informed consent form before the study;\n2. Meets the diagnostic criteria in the \"Clinical Diagnosis and Treatment Guidelines for Adult Femoral Head Necrosis in China (2020)\";\n3. Age range: 20 - 65 years old (inclusive of boundary values), gender not restricted;\n4. Staged as ARCO II stage;\n5. Non-traumatic femoral head necrosis;\n6. Has received conservative treatment (such as physical therapy, blood-activating, analgesic drugs, etc.) for more than 2 weeks, and the target hip joint still shows persistent pain symptoms;\n7. The subjects are usually able to move, not bedridden or in a wheelchair for a long time, and can walk more than 50 meters without the help of crutches or walking sticks;\n8. During the trial period and within 90 days after the surgery, the subjects have no pregnancy plans and voluntarily take effective contraceptive measures.\n\nExclusion Criteria:\n\n1. Based on the researcher's judgment, the subjects had a history of trauma and the injury affected the target hip joint;\n2. In the six months prior to screening, there were obvious injuries involving the target hip joint;\n3. The subject's femoral head necrosis was due to other diseases affecting the hip joint (such as rheumatoid arthritis, psoriatic arthritis, gouty arthritis, symptomatic cartilage calcification, bone necrosis, active infection), or according to the researcher's judgment, peripheral or central nervous system lesions that might affect the assessment of pain and function of the target hip joint (such as back pain, knee joint disease, intervertebral disc protrusion, sciatic nerve pain, fibromyalgia, diabetic neuropathy, etc.);\n4. The femoral head of the target hip joint had obvious necrosis, collapse, joint fusion, etc.;\n5. Those who had a history of hip joint replacement, arthroplasty, or other hip joint surgeries, or planned to undergo surgical treatment of any lower limb\u002Fhip joint during the study period;\n6. The target hip joint had suppurative arthritis or a previous history;\n7. The target hip joint had obvious joint effusion;\n8. During the screening period, the target hip joint had active joint infection or skin ulceration, infection in the surgical area, or any significant chronic skin disease that might interfere with the surgical procedure;\n9. The subject was treating the target hip joint, and within 30 days before screening, had used opioids or glucocorticoids for treatment; or was required to use opioids or glucocorticoids for long-term treatment during the study period;\n10. Patients who had received any drug injection or surgical treatment in the hip joint (both sides or any one side) within 6 months before the treatment start;\n11. Started using drugs such as cilostazol for promoting blood circulation and anticoagulation therapy 8 weeks before screening;\n12. Note: If antihypertensive drugs or anticoagulant drugs such as cilostazol were used for treatment for ≥ 8 weeks before screening, they could be used at a stable dose during the study period;\n13. The subject had a disease requiring systemic glucocorticoid treatment;\n14. Abnormal liver and kidney function: At the time of screening, AST or ALT \\> 2 × upper limits of normal (ULN); or serum creatinine \\> 1.5 × ULN, or creatinine clearance rate ≤ 50 mL\u002Fmin;\n15. Note: For men, the creatinine clearance rate (mL\u002Fmin) = \\[(140 - age) × weight (kg)\\] \u002F \\[0.818 × Cr (μmol\u002FL)\\]; for women, the creatinine clearance rate (mL\u002Fmin) = male creatinine clearance rate (mL\u002Fmin) × 0.85;\n16. The subject had any type of active malignant tumor and was receiving systemic chemotherapy; or within 5 years before screening, was diagnosed with cancer (excluding squamous cell carcinoma or basal cell carcinoma of the skin);\n17. According to the researcher's judgment, before enrollment, 12-lead electrocardiogram (ECG) showed clinically significant abnormalities; including QTc (QTcB) \\> 450 ms, or heart rate \\> 100 bpm, or QRS \\> 120 ms, or PR \\> 220 ms;\n18. Basic cardiovascular diseases: Within 6 months before enrollment, had experienced the following cardiovascular events: myocardial infarction or coronary artery bypass surgery or traumatic coronary artery reperfusion surgery or stroke; unstable angina pectoris; variant angina pectoris; symptomatic congestive heart failure (New York Heart Association cardiac function grade III-IV or ejection fraction ≤ 35%);\n19. Uncontrolled hypertension (defined as systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg after standardized antihypertensive drug treatment);\n20. Positive hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, syphilis antibody tests;\n21. Those who are known or suspected to be allergic to the active or inactive ingredients of the research drug;\n22. Gastrointestinal underlying diseases: having a history of gastrointestinal bleeding or perforation after using non-steroidal anti-inflammatory drugs (NSAIDs); subjects with active gastrointestinal ulcer bleeding within 30 days before enrollment, or who have had recurrent ulcer bleeding in the past;\n23. Allergic to the test drug or having a history of hypersensitivity reaction;\n24. Subjects unable to avoid non-habitual physical activities (such as starting new weightlifting exercises);\n25. Having a clear history of mental disorder, or having a history of abuse of psychotropic drugs or drug addiction;\n26. Alcohol (defined as drinking more than 2 units per day\u002F more than 14 units per week, 1 unit being equivalent to 360ml of beer or 45ml of 40% alcohol content spirits or 150ml of wine) or drug abusers; or those with mental disorders;\n27. Pregnant women, lactating women, and women of childbearing age who have not undergone sterilization surgery\u002Fare not in menopause\u002Fare unwilling to use medically approved effective contraceptive measures during the study period; men who have not undergone sterilization surgery\u002Fare unwilling to use medically approved effective contraceptive measures during the study period;\n28. Those who have participated in any other clinical trials within 3 months before screening;\n29. Other situations deemed unsuitable for participation in this trial by the investigator.",{"count":199,"type":23},[114],"The commercial decalcified bone scaffold combined with the patient's autologous bone marrow mesenchymal stem cells was used for in vitro culture to form tissue-engineered bone, and the effect of this tissue-engineered bone in early non-traumatic femoral head necrosis was explored.",[287],"Avascular Necrosis of Femur Head",{"date":253,"type":35},{"date":273,"type":23},{"date":275,"type":23},{"name":41,"class":42},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":110,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":309,"leadSponsor":311,"locationsCount":43},"100634894","screening-for-biomarkers-of-osteonecrosis-of-the-femoral-head-100634894","NCT07545616","Screening for Biomarkers of Osteonecrosis of the Femoral Head","Screening of Biomarkers for Osteonecrosis of the Femoral Head and Establishment of a Multidimensional Data Based Early Diagnostic Method","Inclusion Criteria:\n\n1. Aged between 18 and 70 years old (inclusive).\n2. Patients with suspected ONFH.\n3. Those who provide informed consent and volunteer to participate in this study.\n\nExclusion Criteria:\n\n1. Patients with a clear history of hip trauma.\n2. Patients with ONFH secondary to traumatic factors such as femoral neck fracture and hip dislocation.\n3. Patients complicated with severe mental illness or cognitive impairment who are unable to cooperate with questionnaire completion.\n4. Patients who refuse to sign the informed consent form.",{"count":300,"type":23},300,"Osteonecrosis of the femoral head (ONFH) presents a rapidly progressive natural disease course. Femoral head collapse may occur within two years, ultimately necessitating total hip arthroplasty and imposing a heavy medical and economic burden on patients. Early intervention can significantly improve the long-term prognosis of ONFH. However, due to the lack of validated biomarkers for early diagnosis, the early diagnostic rate remains low, with a primary diagnostic rate of merely 68.43% at the first visit, accompanied by a high rate of misdiagnosis. This project intends to collect blood samples from patients diagnosed with ONFH and suspected cases in the orthopedic outpatient department of a tertiary Grade A hospital. Diagnostic and differential diagnostic tests will be adopted to evaluate the clinical application value of previously reported candidate biomarkers, so as to screen out biomarkers with excellent diagnostic validity and reliability. Meanwhile, clinical data will be collected to identify independent risk factors, and a multi-dimensional integrated diagnostic model will be further established. The research findings are expected to provide solid data support, theoretical basis and technical reserves for the early prevention, early diagnosis and individualized intervention of osteonecrosis of the femoral head.",[303],"Osteonecrosis of the Femoral Head",[303,305],"Biomarker",{"date":307,"type":35},"2026-04-22",{"date":273,"type":23},{"date":310,"type":23},"2027-05-30",{"name":41,"class":42},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":51,"minAge":319,"maxAge":110,"enrollmentInfo":320,"targetDuration":321,"studyType":24,"phases":4,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":331,"locationsCount":43},"100634833","screening-for-biomarkers-of-osteoarthritis-100634833","NCT07544823","Screening for Biomarkers of Osteoarthritis","Screening of Biomarkers for Osteoarthritis and Establishment of a Multidimensional Data Based Early Diagnostic Method","Inclusion Criteria:\n\n1. Aged between 40 and 70 years (inclusive);\n2. Joint pain or stiffness lasting for no less than 3 months;\n3. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. Combined with other severe joint diseases, such as rheumatoid arthritis, gout, etc.;\n2. Suffering from severe systemic diseases, such as heart failure, malignant tumors and others;\n3. Received joint surgery within the past 3 months or taking medications that may affect the progression of osteoarthritis;\n4. Individuals with cognitive dysfunction who are unable to cooperate with the research procedures;\n5. Failure to complete X-ray, MRI examination or follow-up visits as required.","40 Years",{"count":300,"type":23},"5 Years","Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide, which causes pain, loss of joint function and declined quality of life, and ranks as the leading cause of disability among individuals aged over 60 years. In China, the number of patients with osteoarthritis is projected to exceed 200 million by 2044, resulting in a continuously growing demand for medical resources and escalating economic burden.Nevertheless, the lack of effective biomarkers for early diagnosis leads to advanced disease conditions at the time of initial medical consultation and delayed treatment. This project intends to collect blood samples from OA patients and suspected patients in the orthopedic outpatient department of a tertiary hospital. Diagnostic and differential diagnostic tests will be adopted to verify the clinical application value of previously reported candidate biomarkers, so as to screen out biomarkers with favorable validity and reliability. The research findings are expected to provide data support and theoretical basis for the early prevention, early diagnosis and individualized intervention of osteoarthritis.",[324],"Osteoarthritis (OA)",[326,305],"Osteoarthritis",{"date":307,"type":35},{"date":273,"type":23},{"date":330,"type":23},"2026-12-30",{"name":41,"class":42},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":339,"minAge":52,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":55,"phases":343,"briefSummary":344,"conditions":345,"keywords":350,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100633694","clinical-efficacy-and-mechanisms-of-a-topical-azone-tranexamic-acid-aloe-polysaccharide-gel-in-the-treatment-of-melasma-100633694","NCT07530016","Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma","Melasma is a Common Pigmented Skin Disease, Related to Genetics and Ultraviolet Rays, and Prone to Causing Psychological Problems. The Current Treatments Have Limitations. The Combination Gel of Tranexamic Acid, Aloe Polysaccharide and Lauric Azonide is Expected to Enhance Efficacy and Reduce Side Effects. This Study Explores Its Therapeutic Effect and Mechanism, Providing New Strategies.","Inclusion Criteria:\n\nAdult patients aged 18-50 years diagnosed with melasma Famale\n\nExclusion Criteria:\n\n* Patients with contraindications to melatonin, including pregnancy, breastfeeding, autoimmune disorders, bleeding disorders, and diabetes, or contraindications to tranexamic acid, including thromboembolic events, history of thrombosis, renal impairment, and pregnancy or breastfeeding.\n\nPatients with a history of hypersensitivity to any of the medications. Patients already taking treatment of melasma","FEMALE","50 Years",{"count":342,"type":23},10,[114],"Melasma is a common pigmentation disorder among young and middle-aged women, characterized by symmetrical brown-black patches on the face. It is related to genetics, ultraviolet radiation, endocrine factors and inflammation, and can lead to psychological problems and affect quality of life. Current treatments such as hydroquinone stimulation, laser therapy, and oral tranexamic acid have a high recurrence rate and poor compliance. The new gel formulation, which combines tranexamic acid (to inhibit tyrosinase), aloe polysaccharides (anti-inflammatory and repair), and lauric azon (promotes penetration), is expected to enhance efficacy and reduce side effects. This study aims to explore its clinical efficacy and synergistic mechanism, providing new strategies for the treatment of Melasma.",[346,347,348,349],"Melasma","Treatment of Stable Melasma","Tranexamic Acid","Laurocapram",[351,352],"Improve transdermal efficiency","Treatment of stable melasma","2026-04-08",{"date":355,"type":35},"2026-04-14",{"date":357,"type":23},"2026-08-12",{"date":359,"type":23},"2028-11-16",{"name":41,"class":42},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":367,"targetDuration":369,"studyType":24,"phases":4,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":4},"100629581","exploration-study-of-molecular-biomarkers-for-tumor-related-anxiety-and-depression-100629581","NCT07476534","Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression","Inclusion Criteria:\n\n1. Patients with solid tumors aged ≥18 years and an expected survival period of ≥3 months;\n2. Patients who meet clinical diagnostic criteria and are pathologically\u002Fhistologically confirmed as having solid tumors, including liver cancer patients (diagnosable by imaging);\n3. Patients who can complete standardized stratified assessments for tumor-related anxiety and depression, and are able to cooperate with researchers in completing psychological scales such as the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS). They have not received any anti-anxiety\u002Fdepression medications, professional psychological counseling, or psychiatric interventions before scale assessment;\n4. Patients with clear consciousness, normal language communication, comprehension, and cognitive abilities, without a history of psychiatric disorders, and who can independently provide feedback on research-related information and cooperate with follow-up;\n5. Patients who voluntarily participate in the study, fully understand the research objectives, procedures, potential risks, and benefits, and have signed a written informed consent form;\n6. Patients who can cooperate in completing the required laboratory tests (complete blood count, blood biochemistry, coagulation function, etc.) and clinical data collection before and during the perioperative period to ensure the completeness of research data.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Patients aged \\\u003C21 years at first visit and with an expected survival period of \\\u003C3 months;\n3. Patients who have previously received anti-anxiety\u002Fdepression medications or professional psychological interventions;\n4. Patients with a history or current diagnosis of psychiatric disorders, including schizophrenia, bipolar disorder, severe cognitive dysfunction, mental retardation, or those who cannot cooperate with SAS\u002FSDS scale assessment or have contraindications to scale evaluation;\n5. Patients with severe organ dysfunction or severe underlying diseases, including: liver failure (Child-Pugh C grade), renal failure (serum creatinine \\>250 μmol\u002FL or \\>2.83 mg\u002FdL), New York Heart Association (NYHA) Class IV heart failure, active pulmonary tuberculosis, HIV infection, etc. (to be determined);\n6. Patients with contraindications to tumor tissue or blood sample collection, including coagulation disorders (INR \\>1.5, platelets \\\u003C50×10⁹\u002FL), severe bleeding tendency, or surgical specimens that cannot meet detection requirements (e.g., \\>50% necrotic tissue, insufficient tissue amount);\n7. Patients with emotional abnormalities due to non-tumor factors, including hyperthyroidism\u002Fhypothyroidism, severe malnutrition, chronic wasting diseases, or psychological stress disorders;\n8. Patients who have undergone non-tumor-related surgical procedures, enteral\u002Fparenteral nutrition support within the past 1 month, or have clinical symptoms such as gastrointestinal mechanical obstruction, intractable vomiting, ascites, significant edema, or large pleural effusion;\n9. Patients who are planned or currently using medications that may affect emotional assessment or protein expression detection during the study, including: long-term oral corticosteroids, 5-HT receptor agonists\u002Fantagonists (SSRIs, etc., even short-term use within 2 weeks before sampling is excluded), antipsychotic drugs, or gestagenic synthetic steroid derivatives (short-term inhaled\u002Flocal use of steroids or intermittent use of inhaled bronchodilators are excluded);\n10. Patients with incomplete clinical data, inability to cooperate with research-related follow-up and testing, or those who refuse to sign the informed consent form or have poor compliance.",{"count":368,"type":23},100,"6 Months","Identifying and validating molecular biomarkers associated with tumor-related anxiety and depression. By integrating psychological assessment data from clinical tumor patients with molecular detection results, and utilizing clinically accessible samples such as tumor tissues and sera from clinical cohorts, this study aims to clinically validate the tumor-derived proteins previously identified by our team as having potential regulatory roles. The goal is to clarify the clinical value of tumor-derived proteins as molecular biomarkers for tumor-related anxiety and depression, providing a molecular basis for early screening and risk stratification. Alternatively, it seeks to establish a tumor-related anxiety and depression risk assessment model based on the expression levels of tumor-derived proteins, offering a reference for the precise identification and targeted intervention of psychological disorders in tumor patients.",[372],"Solid Tumor Malignancies",[374,375,376],"Solid tumor malignancies","Anxiety","Depression","2026-03-12",{"date":379,"type":35},"2026-03-17",{"date":381,"type":23},"2026-03-01",{"date":383,"type":23},"2026-12-01",{"name":41,"class":42},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":51,"minAge":393,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":55,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":4},"100621896","efficacy-and-safety-of-anricofen-combined-with-ciprofol-for-deep-sedation-in-elderly-patients-undergoing-ercp-100621896","NCT07376577","Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP","A Randomized Controlled Trial on the Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography","Anricofen Cipr","Inclusion Criteria:\n\n\\-\n\nInclusion Criteria:\n\n1. Age 60-90 years.\n2. American Society of Anesthesiologists (ASA) physical status II or III.\n3. Scheduled for elective endoscopic retrograde cholangiopancreatography (ERCP).\n4. Body mass index (BMI) between 18 and 30 kg\u002Fm².\n5. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Severe neurological disorders (acute stroke, uncontrolled seizures, epilepsy).\n2. Psychiatric disorders or cognitive impairment (Mini-Mental State Examination score \\\u003C24).\n3. Uncontrolled hypertension (preoperative blood pressure ≥180\u002F110 mmHg) or hypotension (\\\u003C90\u002F60 mmHg).\n4. Severe cardiac disease: sinus bradycardia, sick sinus syndrome, unstable angina, or myocardial infarction within the past 3 months.\n5. Severe hepatic or renal dysfunction.\n6. Difficult airway or severe respiratory disease.\n7. Achalasia.\n8. Known allergy to anricofen, sufentanil, ciprofol, or other study medications.\n9. Use of opioid analgesics or sedatives within 7 days prior to surgery.\n10. Preoperative pulse oxygen saturation (SpO₂) \\\u003C90% on room air.\n11. Pregnancy or lactation.\n12. Participation in any other drug clinical trial within the past 3 months.\n13. Refusal to participate in the study.\n\nExclusion Criteria:\n\n\\-","60 Years","90 Years",{"count":396,"type":23},141,[114],"Background: Endoscopic retrograde cholangiopancreatography (ERCP) is a key technique for treating pancreatobiliary diseases in the elderly. However, traditional sedative and analgesic regimens (e.g., sufentanil combined with propofol) are associated with a high incidence of respiratory depression, postoperative nausea and vomiting (PONV), and delayed recovery in elderly patients. Anricofen is a novel peripherally selective κ-opioid receptor agonist that provides analgesia with minimal central respiratory depression. Ciprofol is a new sedative agent characterized by rapid onset and quick recovery. The combination of these two drugs may offer a safer sedation and analgesia regimen for elderly patients undergoing ERCP.\n\nObjective: To evaluate the efficacy and safety of anricofen combined with ciprofol for deep sedation in elderly patients undergoing ERCP, compared with the traditional regimen (sufentanil combined with ciprofol).\n\nMethods: This is a single-center, randomized, double-blind, controlled trial. A total of 141 elderly patients aged 60-90 years with ASA physical status II-III scheduled for elective ERCP will be enrolled and randomly assigned in a 1:1:1 ratio to three groups: Anricofen 0.3 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg, Anricofen 0.5 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg, or Sufentanil 0.1 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg. The primary efficacy endpoint is the intraoperative pain control success rate (proportion of time with Behavioral Pain Scale \\[BPS\\] score ≤3 ≥90%). The primary safety endpoint is the incidence of respiratory depression (respiratory rate \\\u003C10 breaths\u002Fmin or SpO₂ \\\u003C90% requiring intervention). Secondary outcomes include sedation depth, body movement episodes, recovery time, PONV incidence, and others.\n\nSignificance: This study aims to provide a sedation and analgesia regimen with lower risk of respiratory depression and faster recovery for elderly patients undergoing ERCP.",[400,401,402,403],"Anesthesia","Sedation","ERCP","Ciprofol","2026-01-26",{"date":406,"type":35},"2026-01-29",{"date":408,"type":23},"2026-01-01",{"date":410,"type":23},"2028-05-01",{"name":41,"class":42},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":339,"minAge":52,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":55,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":43},"100620827","effects-of-ultrasound-guided-recruitment-manoeuvres-on-postoperative-pulmonary-complications-in-osa-patients-undergoing-total-laparoscopic-hysterectomy-100620827","NCT07362680","Effects of Ultrasound-guided Recruitment Manoeuvres on Postoperative Pulmonary Complications in OSA Patients Undergoing Total Laparoscopic Hysterectomy","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Scheduled for elective total laparoscopic hysterectomy;\n* American Society of Anesthesiologists (ASA) I to III;\n* BMI \\> 28 kg\u002Fm²;\n* STOP-BANG score ≥ 3.\n\nExclusion Criteria:\n\n* Abnormal findings on preoperative chest X-ray or CT, such as atelectasis, pneumothorax, thoracic deformity, pleural effusion, or neuromuscular diseases;\n* Pre-existing severe pulmonary diseases;\n* Severe cardiac arrhythmias or a history of cardiac surgery;\n* Allergy to any medications used in the study.",{"count":156,"type":23},[114],"This study aims to evaluate the lung-protective effects of ultrasound-guided lung recruitment maneuvers in patients with OSA undergoing total laparoscopic hysterectomy and to explore the efficacy of EELV measurement in assessing the effectiveness of these maneuvers.",[422,423],"Total Laparoscopic Hysterectomy","Atelectasis, Postoperative","2026-01-15",{"date":426,"type":35},"2026-01-23",{"date":428,"type":35},"2025-05-02",{"date":430,"type":23},"2026-08-31",{"name":41,"class":42},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":55,"phases":443,"briefSummary":445,"conditions":446,"keywords":449,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":461,"leadSponsor":463,"locationsCount":4},"100619659","phase-4-a-randomized-controlled-clinical-trial-comparing-remimazolam-besylate-combined-with-alfentanil-versus-propofol-combined-with-alfentanil-for-anesthesia-in-thoracic-surgery-100619659","NCT07347496","A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery","A Randomized, Single-blind, Parallel-controlled Clinical Study to Evaluate the Safety and Efficacy of Remimazolam Besylate Combined With Alfentanil in Anesthesia for Thoracic Surgery","RAA-TS","Inclusion Criteria:\n\n* Patients scheduled for elective thoracic surgery (e.g., pulmonary lobectomy, esophagectomy) under general anesthesia with preserved spontaneous respiration.\n* American Society of Anesthesiologists (ASA) physical status class I-III.\n* Age between 18 and 75 years.\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Severe hepatic or renal dysfunction (e.g., Child-Pugh class C, eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n* Severe respiratory dysfunction (e.g., COPD GOLD stage 3-4, severe asthma).\n* Anticipated difficult airway (e.g., Mallampati class IV, history of difficult intubation).\n* Known allergy or hypersensitivity to benzodiazepines, opioids, or propofol.\n* Pregnancy or lactation.\n* Participation in another interventional clinical trial within the past 3 months.\n* Mental illness or inability to cooperate with assessments.","75 Years",{"count":442,"type":23},50,[444],"PHASE4","Title: A Clinical Study Comparing Two Anesthesia Methods for Chest Surgery\n\nWhy is this study being done? Chest surgeries (like lung surgery) require safe and stable anesthesia. Currently, a drug called propofol combined with an opioid painkiller (alfentanil) is commonly used. However, propofol can sometimes cause low blood pressure and low oxygen levels. A newer drug called remimazolam may cause fewer of these side effects. This study aims to compare the safety and effectiveness of remimazolam (combined with alfentanil) versus propofol (combined with alfentanil) for anesthesia during chest surgery.\n\nWhat will happen in the study?\n\nPatients scheduled for elective chest surgery will be invited to participate. If they agree, they will be randomly assigned (like flipping a coin) to one of two groups:\n\n* Group 1: Will receive remimazolam and alfentanil for anesthesia.\n* Group 2: Will receive propofol and alfentanil for anesthesia (standard care).\n\nThe anesthesiologist will carefully monitor patients during and after surgery. We will mainly compare how often patients in each group experience two safety issues: low oxygen levels in the blood and low blood pressure. We will also record recovery times, drug doses, side effects, and ask patients and surgeons about their satisfaction.\n\nWho can participate? Adults aged 18-65 who are scheduled for elective chest surgery and are in relatively stable health (ASA physical status I-III).\n\nWhere is the study taking place? This study will be conducted in the Department of Anesthesiology at The First Affiliated Hospital of Xinxiang Medical College, Henan, China.\n\nEthics Approval:\n\nThis study has been reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Xinxiang Medical College (Approval Number: (2025) Medical Ethics Committee Approval No. 29).",[447,400,448],"Thoracic Surgery","Non-intubated Anesthesia",[450,451,452,453,454,455,456],"Remimazolam","Alfentanil","Propofol","Non-intubated","Tubeless Anesthesia","Spontaneous Ventilation Spontaneous Ventilation","Total Intravenous Anesthesia Total Intravenous Anesthesia","2026-01-09",{"date":459,"type":35},"2026-01-16",{"date":381,"type":23},{"date":462,"type":23},"2028-05-31",{"name":41,"class":42},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":55,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":4},"100617938","early-phase-1-malic-acid-supplementation-combined-with-immunotherapy-in-patients-with-solid-tumors-100617938","NCT07325123","Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors","An Exploratory Study on the Safety and Efficacy of Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors","Inclusion Criteria:\n\n* Aged ≥ 18 years (inclusive), male or female;\n* Patients with malignant solid tumors such as colorectal cancer, lung cancer, and melanoma, confirmed by histopathological or cytological examination;\n* Patients have at least one measurable lesion;\n* Undergoing systematic anti-tumor treatment with immunotherapy;\n* Expected survival time ≥ 3 months;\n* Basic functions of major organs are norma，laboratory tests meet the following criteria：Hematology (No blood transfusion or blood products administered, and no use of G-CSF or other hematopoietic stimulants for correction within 7 days prior to laboratory testing): Absolute neutrophil count ≥ 1.5×10⁹\u002FL; Platelets ≥ 75×10⁹\u002FL; Hemoglobin ≥ 90g\u002FL. Kidney: Creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) \\> 60ml\u002Fmin\u002F1.73m² (Cockcroft-Gault formula). Liver: Serum total bilirubin \\\u003C 1.5×ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2.5×ULN or ≤ 5×ULN (for subjects with liver metastases); Albumin (ALB) ≥ 30g\u002FL. Coagulation function: International normalized ratio (INR) or prothrombin time (PT) \\\u003C 1.5×ULN. For subjects receiving anticoagulant therapy, it is acceptable as long as PT is within the intended range for the anticoagulant used.l;\n* For female subjects of childbearing age during the screening period, the serum pregnancy test result must be negative; female\u002Fmale subjects of reproductive potential must be willing to use reliable contraceptive methods throughout the entire study period (i.e., from signing the informed consent form to 90 days after the last administration of the study drug), including but not limited to: abstinence, vasectomy of the male partner, female sterilization, effective intrauterine devices (IUDs), and effective contraceptive medications.\n* Patients voluntarily participate in this study, sign the informed consent form, and have good compliance.\n\nExclusion Criteria:\n\n* Subjects who have not recovered from adverse events caused by any intervention to ≤ Grade 1 (except for alopecia, hearing impairment, and Grade ≤ 2 neurological or endocrine disorders requiring replacement therapy) prior to the first dose;\n* Subjects who have undergone major or moderate surgery (other than for diagnosis or biopsy) within 28 days prior to the first dose, or are expected to undergo major surgery during the study;\n* Subjects with severe chronic obstructive pulmonary disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease \\[GOLD\\] ≥ Grade 3), or who have had intestinal adhesions or intestinal obstruction within 6 months prior to the first dose;\n* Subjects with severe cardiovascular diseases, such as New York Heart Association (NYHA) Heart Disease (Class III or higher), myocardial infarction within 6 months, current unstable angina, or uncontrolled hypertension (systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg);\n* Subjects with uncontrolled primary brain tumors or central nervous system (CNS) metastases, with significant intracranial hypertension or neuropsychiatric symptoms;\n* Subjects with uncontrollable neuropsychiatric diseases, mental disorders, or substance abuse, which may affect trial compliance;\n* Subjects with active infections requiring systemic treatment;\n* Subjects with a known history of human immunodeficiency virus (HIV) infection;\n* Subjects with hepatitis B virus (HBV) infection (HBsAg-positive or HBcAb-positive, with HBV-DNA ≥ 2000 IU\u002FmL or HBV-DNA ≥ 10⁴ copies\u002FmL), or hepatitis C virus (HCV) infection (HCV antibody-positive, with HCV-RNA quantitative test result above the lower limit of detection); Note: For subjects with HBV infection and HBV-DNA \\\u003C 2000 IU\u002FmL or HBV-DNA \\\u003C 10⁴ copies\u002FmL, those who are willing to receive antiviral therapy (such as entecavir, tenofovir, or other antiviral drugs) based on clinical judgment during the study may be enrolled;\n* Subjects with medical history, diseases, treatments, or laboratory abnormalities that may interfere with trial results, prevent the subject from completing the entire study, or are deemed by the investigator as not being in the subject's best interest to participate in the study.",{"count":199,"type":23},[57],"This is a study on the safety and efficacy of malic acid supplementation combined with immunotherapy for anti-tumor treatment in patients with solid tumors. The primary study objective is to determine the oral safety of malic acid; Secondary study objectives: 1. To evaluate the preliminary efficacy of malic acid in the study population. 2. To determine the recommended phase 2 dose (RP2D) of oral malic acid. Exploratory endpoints: Immune indicators including white blood cell count, neutrophil, lymphocyte, monocyte, eosinophil and basophil (count\u002Fproportion); metabolic indicators including blood glucose, triglycerides; nutritional indicators including body weight.",[372],"2025-12-29",{"date":477,"type":35},"2026-01-08",{"date":479,"type":23},"2025-12-31",{"date":481,"type":23},"2027-12-31",{"name":41,"class":42},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":217,"enrollmentInfo":490,"targetDuration":4,"studyType":55,"phases":491,"briefSummary":492,"conditions":493,"keywords":498,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":43},"100598033","bone-reconstruction-with-autologous-bone-marrow-mesenchymal-stem-cells-in-vitro-to-repair-long-tubular-bone-defects-100598033","NCT07066228","Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects","Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects of Limbs","Inclusion Criteria:\n\n1. Age: 18-55 years old, gender unrestricted;\n2. Defective nonunion with bone loss exceeding 30% of the bone cross-section and a length of 2-3 cm;\n3. Solitary bone cysts involving more than 50% of the bone cross-section.\n\nExclusion Criteria:\n\n1. Combined with local tumors, tuberculosis, infections or other bone-healing affecting lesions;\n2. Systemic diseases affecting bone healing such as osteofibrous dysplasia, osteogenesis imperfecta, bone dystrophic diseases, and metabolic bone disorders;\n3. Moderate-to-severe osteoporosis (BMD: T-score \\\u003C -2.5);\n4. Severe systemic conditions including systemic malnutrition, systemic infectious diseases, severe cardiopulmonary diseases, coagulation disorders, and major organ failure;\n5. Complicated with severe brain trauma;\n6. Heavy smoking, drug abuse, alcoholism, or other harmful addictions;\n7. Psychiatric disorders or patients with menopausal symptoms;\n8. Concurrent participation in other studies or recent completion (within 4 weeks) of other clinical trials;\n9. Pregnancy, lactation, or planned pregnancy within one year after initial enrollment;\n10. Psychological conditions impairing treatment compliance;\n11. Congenital malformations of vital organs or other systems;\n12. Nonunion caused by malignant tumor resection;\n13. Refusal to accept tissue-engineered bone repair protocol.",{"count":199,"type":23},[114],"Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro to explore the effect of this tissue engineered bone in the clinical repair of long tubular bone defects in limbs.",[494,495,496,497],"Defective Composite Restorations","Bone Cysts","Bone Defect","Bone Nonunion",[499,500,501],"autologous bone marrow mesenchymal stem cells","DBM","long tubular bone defects of limbs","2025-12-28",{"date":504,"type":35},"2026-01-02",{"date":506,"type":35},"2025-08-07",{"date":275,"type":23},{"name":41,"class":42},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":55,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":43},"100612977","phase-1-vsv-02-compassionate-use-in-advanced-solid-tumors-100612977","NCT07260591","VSV-02 Compassionate Use in Advanced Solid Tumors","A Single-Arm, Open-Label, Compassionate Use Study of VSV-02 Administered Intravenously and Intratumorally in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\nVoluntary signed informed consent.\n\nAge ≥ 18 years.\n\nHistologically or cytologically confirmed advanced solid tumor (e.g., melanoma, head and neck squamous cell carcinoma, cervical cancer, osteosarcoma, nasopharyngeal carcinoma, breast cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer).\n\nDisease progression after at least two prior lines of standard therapy (including targeted therapy), or for whom no standard therapy exists or is medically unsuitable.\n\nAt least one measurable lesion per RECIST 1.1 criteria.\n\nAt least one lesion accessible for intratumoral injection.\n\nECOG performance status of 0-2.\n\nLife expectancy ≥ 12 weeks.\n\nAdequate organ and bone marrow function.\n\nNegative pregnancy test for women of childbearing potential.\n\nAgreement to use effective contraception during the study and for at least 6 months after the last dose.\n\nExclusion Criteria:\n\nSymptomatic or untreated brain metastases (asymptomatic or stable for ≥3 months after local therapy allowed).\n\nRadiotherapy to the target lesion within 2 months.\n\nHistory of other active malignancy within 5 years (with specific exceptions).\n\nLesion intended for injection with a longest diameter \\> 100 mm.\n\nParticipation in another interventional clinical trial within 4 weeks.\n\nPrior or planned organ\u002Ftissue transplantation.\n\nActive HIV, Hepatitis B, Hepatitis C, or Syphilis infection meeting specific criteria.\n\nRequirement for concomitant antiviral or therapeutic anticoagulation.\n\nUncontrolled ≥ Grade 3 active infection.\n\nSpecific washout periods for prior anti-cancer therapies not met.\n\nUncontrolled cardiovascular disease.\n\nActive or history of autoimmune disease (with specific exceptions).\n\nRequirement for systemic corticosteroids (\\>10 mg prednisone equivalent) within 14 days or during the study.\n\nTumors located in high-risk anatomical sites.\n\nAdministration of live vaccines during the study period.\n\nKnown hypersensitivity to any component of the study drug or related immunotherapies.\n\nHistory of severe mental illness, substance abuse, or other conditions that may interfere with study compliance.\n\nPregnancy or lactation.\n\nToxicities from previous anti-cancer therapy not recovered to ≤ Grade 1 (except alopecia).\n\nAny other condition deemed inappropriate for participation by the investigator.",{"count":517,"type":23},6,[246],"This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational drug called VSV-02 Injection, which is developed by Shanghai Rongrui Pharmaceutical Technology Co., Ltd.\n\nThe main purpose of this open-label, single-arm study is to assess the preliminary effectiveness and safety of VSV-02 when it is given through two routes: directly into a vein (intravenously) and by injection directly into the tumor (intratumorally). Patients will receive the treatment on the first day of each 3-week cycle, for up to 6 cycles.\n\nThe study will follow a dose-escalation design to find a suitable dose. Treatment may be stopped if the disease progresses, if side effects become intolerable, or if the patient chooses to withdraw, among other reasons. Researchers will closely monitor patients to see if VSV-02 can help control the cancer and to record any side effects that may occur.",[521,522,523,524,525,526],"Advanced Solid Tumor","Melanoma","Breast Cancer","Lung Cancer","Cancer Treatment","Immunotherapy","2025-11-28",{"date":529,"type":35},"2025-12-03",{"date":531,"type":35},"2025-09-22",{"date":533,"type":23},"2027-09-30",{"name":41,"class":42},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":55,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":4},"100606673","phase-1-assessment-of-the-dose-safety-and-efficacy-of-serine-combined-with-fluorouracil-drugs-100606673","NCT07178613","Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs","Inclusion Criteria:\n\n1. Age ≥ 18 years (inclusive), male or female;\n2. Patients with advanced colorectal cancer confirmed by histopathological or cytological examination, eligible for standard first-line treatment with fluorouracil-containing regimens.\n3. Patients must have at least one measurable lesion.\n4. ECOG performance status ≤ 2.\n5. Expected survival ≥ 3 months;\n6. Major organ functions are essentially normal, with laboratory tests meeting the following criteria:\n\n   Hematology (no transfusion of blood or blood products within 7 days prior to testing; no use of G-CSF or other hematopoietic growth factors for correction):\n\n   Absolute neutrophil count ≥1.5×10⁹\u002FL ; Platelets ≥75×10⁹\u002FL ; Hemoglobin ≥90 g\u002FL;\n\n   Renal:\n\n   Creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) \\>60 mL\u002Fmin\u002F1.73 m² (Cockcroft-Gault formula);\n\n   Liver:\n\n   Serum total bilirubin \\\u003C1.5×ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C2.5×ULN or ≤5×ULN (for subjects with liver metastases); Albumin (ALB) ≥30 g\u002FL;\n\n   Coagulation Function:\n\n   International Normalized Ratio (INR) or Prothrombin Time (PT) \\\u003C 1.5×ULN. If the subject is receiving anticoagulant therapy, PT is acceptable as long as it falls within the therapeutic range for the anticoagulant drug.\n\n   Cardiovascular System:\n\n   Ejection Fraction (EF) 55%-70%; QTc Interval: Male ≤440ms; Female ≤450ms.\n7. Serum pregnancy tests for female subjects of childbearing potential during the screening period must be negative. Female\u002Fmale subjects with reproductive potential must be willing to use reliable contraception throughout the study period (i.e., from signing the informed consent form until 90 days after the last study drug administration), including but not limited to: abstinence, male partner having undergone vasectomy, female sterilization, effective intrauterine device (IUD), and effective contraceptive medication.\n8. Patients voluntarily participate in this study, sign informed consent forms, and demonstrate good compliance.\n\nExclusion Criteria:\n\n1. Trial Participation Restrictions: Currently participating in or having received investigational drug\u002Fdevice treatment within the past 4 weeks;\n2. Prior Fluorouracil-Based Therapy Restrictions: History of ≥Grade 3 toxicity (e.g., myelosuppression, gastrointestinal toxicity) following prior fluorouracil-based therapy, deemed unsuitable for re-administration by the investigator;\n3. Recent Surgery Restriction: Undergone major surgery (excluding diagnostic biopsy) within 28 days prior to first dosing, or scheduled for surgery during the study period;\n4. Metabolic and Nutritional Status Restriction: Presence of severe malnutrition (BMI \\\u003C 18.5 or serum albumin \\\u003C 30 g\u002FL), or inability to supplement serine orally (e.g., malabsorption syndrome, short bowel syndrome); Known serine metabolism disorders (e.g., PHGDH\u002FPSAT1 gene mutation-related diseases);\n5. Concurrent severe disease restrictions: Severe cardiovascular disease (NYHA Class III\u002FIV heart failure, myocardial infarction within 6 months, uncontrolled hypertension \\>150\u002F100 mmHg); severe respiratory disease (COPD, GOLD Stage ≥3, interstitial lung disease); Active infection (requiring systemic antibiotic\u002Fantiviral therapy);\n6. Active HIV\u002Fviral hepatitis: HIV-positive status, or active hepatitis B (HBV-DNA ≥ 2000 IU\u002FmL), or active hepatitis C (HCV-RNA positive); (Note: Patients with HBV-DNA \\\u003C 2000 IU\u002FmL receiving antiviral therapy may be enrolled);\n7. Neurological disorders: Uncontrolled brain metastases (with intracranial hypertension or neurological symptoms), or history of severe psychiatric illness\u002Fsubstance abuse (impeding treatment compliance);\n8. Allergy history: Known allergy to fluorouracil-based drugs or serine supplements;\n9. Pregnancy\u002Flactation: Pregnant or lactating women (patients of childbearing potential must use highly effective contraception);\n10. Other conditions deemed ineligible by the investigator: Any concomitant conditions or laboratory abnormalities that may interfere with study results, increase risk, or compromise patient safety.",{"count":542,"type":23},20,[246],"This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.\n\nSecondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine.",[546],"Advanced Colorectal Cancer","2025-09-10",{"date":549,"type":35},"2025-09-17",{"date":551,"type":23},"2025-11",{"date":553,"type":23},"2026-02",{"name":41,"class":42},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":55,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":43},"100603454","ai-assisted-comprehensive-management-for-cancer-patients-with-comorbidities-gcog-cg001-100603454","NCT07136727","AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)","The Impact of Multimodal Digital Fusion AI-Assisted Decision Support System-Based Comprehensive Management on Clinical Outcomes in County-Level Patients With Comorbid Cancer:A Prospective Non-randomized Controlled Interventional Study.","GCOG-CG001","Inclusion Criteria:\n\n* Patients with a definite diagnosis of malignancy by histopathology and\u002For cytology;\n* Age ≥18 years;\n* There is no gender limit\n* Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ;\n* Conscious and able to answer questions and use electronic devices autonomously;\n* Patients were able to understand the study and voluntarily sign an informed consent form;\n\nExclusion Criteria:\n\n* Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme;\n* With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness;\n* Women during pregnancy or lactation；\n* Have participated in other interventional studies in the past 1 month or are currently participating;\n* Patients with ECOG ≥ 3 that do not respond to treatment;\n* Patients with an expected survival of \\\u003C 3 months that do not respond to treatment;\n* Cases deemed unsuitable for enrollment by the investigator.",{"count":564,"type":23},5000,[114],"Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.",[568],"Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition)",[570,571,572],"Malignant neoplasm","Comorbidity","Artificial intelligence","2025-08-20",{"date":575,"type":35},"2025-08-22",{"date":577,"type":23},"2025-08-15",{"date":579,"type":23},"2031-05-01",{"name":41,"class":42},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":17,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":590,"conditions":591,"keywords":594,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":4},"100603048","serum-histone-succinylation-as-a-novel-prognostic-biomarker-in-hematological-malignancies-100603048","NCT07131449","Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies","succinylation","Inclusion Criteria tumor group\n\n1. ≥ 18 years old , regardless of gender;\n2. Hematological malignancies confirmed by cytology, histology , or molecular biology (such as leukemia, lymphoma, multiple myeloma, etc.), who require subsequent anti-tumor treatment ( chemotherapy , hematopoietic stem cell transplantation, radiotherapy, or cellular immunotherapy ) ; control group\n\n1)≥ 18 years old , regardless of gender; 2)Non-cancer patients undergoing health checkups;\n\nExclusion criteria\n\n1. Pregnant women\n2. Those with severe mental disorders or language communication barriers\n3. Other circumstances that the researcher judges to be unsuitable for participation in this study",{"count":589,"type":23},200,"4\\. Study Population 4.1 Inclusion Criteria Case group\n\n1)≥ 18 years old , regardless of gender; 2)Hematological malignancies confirmed by cytology, histology , or molecular biology , who require subsequent anti-tumor treatment ( chemotherapy , hematopoietic stem cell transplantation, radiotherapy, or cellular immunotherapy ) ; control group\n\n1. ≥ 18 years old , regardless of gender;\n2. Non-cancer patients undergoing health checkups;\n\n4.2 Exclusion criteria\n\n1. Pregnant women\n2. Those with severe mental disorders or language communication barriers\n3. Other circumstances that the researcher judges to be unsuitable for participation in this study The control group was the same as the case group V. Research Design 5.1 Overall Design This study was a single-center prospective case-control study. 5.2 Research Design Process 5.2.1 Study the specific implementation process 1. Phase 1: Screening population for enrollment i. Conduct ethical review and clinical research plan review for the project; ii. 200 patients with hematological malignancies will be selected , basic information collected , and informed consent signed ; iii: 200 healthy subjects are planned to be selected and basic information collected; 2. Second stage: Collect blood samples and perform serum histone succinylation test Blood samples were collected from all 200 eligible participants and 200 healthy subjects for serum histone succinylation testing ; 3. The third stage: statistical analysis of screening results i. Evaluate the differences in serum histone succinylation between patients with hematological malignancies and healthy controls to validate its value in early screening.\n\nii. Statistical analysis of the correlation between serum histone succinylation and tumor efficacy (including chemotherapy , hematopoietic stem cell transplantation, cellular immunotherapy ) and clinical outcomes . ( Efficacy evaluation was performed using RECIST 1.1 criteria )",[592,593],"Leukemia","Lymphoma",[595,596],"leukemia","lymphoma","2025-08-12",{"date":573,"type":35},{"date":600,"type":23},"2025-09-01",{"date":481,"type":23},{"name":41,"class":42},""]